Comparative Pharmacology
Head-to-head clinical analysis: HETLIOZ versus HETLIOZ LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETLIOZ versus HETLIOZ LQ.
HETLIOZ vs HETLIOZ LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melatonin receptor agonist; selective agonist at MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms.
Melatonin receptor agonist; selectively binds to and activates MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms and promoting sleep.
20 mg orally once daily at bedtime, take within 30 minutes of bedtime, with or without food.
20 mg orally once daily at bedtime, taken within 30 minutes of bedtime with or without food. For delayed sleep-wake phase disorder: 0.5 mg/kg (up to 20 mg) once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3-1.5 hours. No clinically relevant accumulation with daily dosing.
Terminal elimination half-life is approximately 1.5-2.0 hours; clinical context: dosing at bedtime aligns with short half-life to avoid residual daytime sedation.
Primarily hepatic metabolism; 77-88% excreted in feces as metabolites, 13-23% in urine as metabolites. <1% excreted unchanged.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites; unchanged tasimelteon in urine <1%; fecal excretion accounts for approximately 80% of total clearance.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist